Soergel David sold $517K of MDGL

Soergel David (Chief Medical Officer) sold 1,042 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $495.74 ($0.52M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soergel David
Published Jun 1, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDGL
Neutral
medium confidence
Mentioned
$MDGL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new clinical, regulatory, or financial information that would typically reset valuation expectations.

02

Market read

For MDGL, the event is best treated as low-signal insider flow rather than a catalyst.

03

What to watch

The sale size ($516.6k) and the 10b5-1 pre-arrangement reduce interpretability; without additional context (e.g., total insider activity trend), signal quality is limited.

Relevance 6/10Novelty 2/10Timing: Filed same day (2026-06-01) for an open-market sale by the CMO.

Background

This is an SEC Form 4 insider transaction: the issuer’s Chief Medical Officer sold shares via an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MDGLNeutralMedium confidence
Context

Madrigal Pharmaceuticals CMO David Soergel sold 1,042 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-01.

Expected impact

Likely minimal immediate price impact; any reaction is more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, and it does not include new company-specific operational or financial information.

Market effects

No clear read-across to the biotech sector because the disclosure is a routine 10b5-1 insider sale without new clinical/regulatory catalysts.

None.

None.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of perceived risk; traders may treat it as a mild caution signal if paired with other negative news.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Company whose CMO disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

  • David Soergel

    Chief Medical Officer who sold 1,042 shares on 2026-06-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.